Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy
- PMID: 20864906
- PMCID: PMC3168988
Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy
Abstract
Introduction: Elevated clotting factors and thrombin generation have been reported to occur in patients with heart failure (HF). Circulating activated factor XI (FXIa) and active tissue factor (TF) can be detected in acute coronary syndromes and stable angina.
Objectives: We investigated circulating FXIa and active TF and their associations in patients with systolic HF due to ischemic cardiomyopathy.
Patients and methods: In an observational study, we assessed 53 consecutive patients, aged below 75 years, with stable HF associated with documented coronary artery disease (CAD). Atrial fibrillation, recent thromboembolic events, and current anticoagulant therapy were the exclusion criteria. Plasma TF and FXIa activity was determined in clotting assays by measuring the response to inhibitory monoclonal antibodies.
Results: Coagulant TF activity was detected in 20 patients (37.7%), and FXIa in 22 patients (41.5%). Patients with detectable TF activity and/or FXIa were younger, had a history of myocardial infarction more frequently, significantly higher F1+2 prothrombin fragments, larger left atrium (LA) and right ventricular diastolic diameter, and higher right ventricular systolic pressure than the remaining subjects (P ≤ 0.01 for all). Circulating FXIa was positively correlated with F1+2 levels (r = 0.69; P < 0.001).
Conclusions: Circulating active TF and FXIa occurred in about 40% of patients with systolic HF due to ischemic cardiomyopathy. The presence of these factors was associated with enhanced thrombin formation. Associations between both factors and LA diameter and right ventricular parameters might suggest that TF and FXIa predispose to thromboembolic complications of HF.
Figures
Similar articles
-
Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients.Blood Coagul Fibrinolysis. 2012 Apr;23(3):189-94. doi: 10.1097/MBC.0b013e32834ee194. Blood Coagul Fibrinolysis. 2012. PMID: 22343680
-
Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.Thromb Res. 2011 Mar;127(3):242-6. doi: 10.1016/j.thromres.2010.11.005. Epub 2011 Jan 13. Thromb Res. 2011. PMID: 21236471 Free PMC article.
-
Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.Eur J Clin Invest. 2012 Feb;42(2):123-9. doi: 10.1111/j.1365-2362.2011.02565.x. Epub 2011 Jun 27. Eur J Clin Invest. 2012. PMID: 21707613 Free PMC article.
-
Anticoagulant drugs targeting factor XI/XIa and coagulation tests: we urgently need reliable pharmacodynamic data.J Thromb Haemost. 2025 May;23(5):1464-1468. doi: 10.1016/j.jtha.2025.02.025. Epub 2025 Mar 6. J Thromb Haemost. 2025. PMID: 40056986 Review.
-
Recent advances in the discovery and development of factor XI/XIa inhibitors.Med Res Rev. 2018 Sep;38(6):1974-2023. doi: 10.1002/med.21503. Epub 2018 May 4. Med Res Rev. 2018. PMID: 29727017 Free PMC article. Review.
Cited by
-
Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.Thromb J. 2015 Jan 23;13(1):4. doi: 10.1186/s12959-015-0038-0. eCollection 2015. Thromb J. 2015. PMID: 25635172 Free PMC article.
-
Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation.Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2334-2345. doi: 10.1161/ATVBAHA.116.308186. Epub 2016 Oct 27. Arterioscler Thromb Vasc Biol. 2016. PMID: 27789475 Free PMC article.
-
The Role of Coagulation in Heart Failure: A Literature Review.Curr Heart Fail Rep. 2024 Aug;21(4):277-291. doi: 10.1007/s11897-024-00671-z. Epub 2024 Jun 13. Curr Heart Fail Rep. 2024. PMID: 38869806 Review.
-
Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.Thromb J. 2020 Nov 7;18(1):32. doi: 10.1186/s12959-020-00245-8. Thromb J. 2020. PMID: 33292285 Free PMC article.
-
Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.J Thromb Thrombolysis. 2013 Feb;35(2):264-70. doi: 10.1007/s11239-012-0821-8. J Thromb Thrombolysis. 2013. PMID: 23086579 Free PMC article.
References
-
- Butenas S, Undas A, Gissel MT, et al. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost. 2008;99:142–149. - PubMed
-
- Kim HK, Song KS, Park YS, et al. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology. 2000;93:31–36. - PubMed
-
- Minnema MC, Peters RJ, de Winter R, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2489–2493. - PubMed
-
- The Stroke Prevention in Atrial Fibrillation Investigators Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med. 1992;116:1–5. - PubMed
-
- Freudenberger RS, Hellkamp AS, Halperin JL, et al. SCD-HeFT Investigators Risk of Thromboembolism in Heart Failure An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Circulation. 2007;115:2637–2641. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous